DAVINDER DHINGRA: Open Payments
NPI 1912065517 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,021 in 38 payments from 7 companies in 2025. Trend: 2023 $936 · 2024 $601 · 2025 $1,021
Food & beverage: $1,021
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 20 | $561 |
| Neurocrine BioSciences, Inc. | 12 | $243 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $120 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
Products named: COBENFY, INGREZZA, CAPLYTA, INVEGA SUSTENNA, FANAPT, ARISTADA, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
